AI MARKET SCANNING

Cellectis S.A.

📅 Next Catalyst: Nov 13, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.72%
MAX GAP RECORD +12.54%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CLLS
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 13, 2026 Earnings Release 2026-11-13 (AFTER CLOSE (21:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (AFTER CLOSE)
+0.37%
May 11, 2026 Earnings Release 2026-05-11 (AFTER CLOSE)
-2.26%
Mar 20, 2026 Earnings Release 2026-03-20 (BEFORE OPEN)
-3.16%
Nov 07, 2025 Earnings Release 2025-11-07 (AFTER CLOSE)
+12.54%
Aug 04, 2025 Earnings Release 2025-08-04 (AFTER CLOSE)
+1.99%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
-5.96%
Mar 13, 2025 Earnings Release 2025-03-13 (AFTER CLOSE)
+8.53%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.0%
Bullish Gaps (4)
Bearish Gaps (5)
Neutral / Flat (5)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CLLS

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗